A Phase II multi-dosing study comparing potency between ARB-1740 and ARB-1467 study in HBV patients
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs ARB 1467 (Primary) ; ARB 1740 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, the company is discontinuing development of ARB-1740.
- 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, status changed from recruiting to completed.
- 10 May 2017 New trial record